Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2020
RemeGen closes approximately $100 million financing
RemeGen announced the closing of approximately US$100 million in private financing, co-led by Lilly Asia Ventures and Lake Bleu Capital. The proceeds were intended to support drug discovery, pipeline development, manufacturing-facility expansion and commercialization efforts for two lead molecules.
2020
Rongchang Biopharmaceutical completes funding round exceeding $100 million
Rongchang Biopharmaceutical completed a funding round of more than $100 million, led by Lilly Asia Ventures and Qingchi Capital, with other investors also participating.